ROCHESTER, N.Y., May 18, 2026—CooperVision has completed enrollment of its global MiSight® 1 day* post-approval clinical studies (PAS) in the U.S. and China, a milestone in real-world evidence generation for pediatric myopia control. Together, these studies represent the longest1-3 international clinical evidence program ever undertaken for soft contact lens-based myopia control intervention in children, including both randomized controlled efficacy trials and large-scale safety registries.1,4-8
The combined PAS programs span more than 100 clinical sites and include over 3,000 children.9 Data will supplement already extensive MiSight® 1 day international clinical studies, which have been widely published and cited in the ophthalmology and optometry communities.1,4-8 Participants in the multi-year studies represent populations across the U.S. and China, providing insights applicable to children worldwide. Final data is expected on a rolling basis between 2027 and 2030.
“As clinicians, we all want long-term, real-world data that mirrors how myopia control is actually practiced,” said Jennifer Palombi, OD, FAAO, Director, Professional Affairs, Americas, CooperVision. “Completing enrollment in these post-approval studies is an important step forward for our category. MiSight® 1 day was built on a strong foundation of clinical evidence, and this next phase will add meaningful insights that can help Eye Care Professionals (ECPs) feel even more confident when managing pediatric myopia and guiding families through long-term care decisions.”1,4-8
The announcement coincides with 2026 Myopia Awareness Week (May 18 – 24), reinforcing the company’s ongoing commitment to advancing the science and understanding of pediatric myopia, a condition expected to affect nearly half of the global population by 2050.10
Building on this latest milestone, CooperVision has also released Progress in Focus: The Global Impact of MiSight® 1 day. The report brings together the far-reaching body of evidence and highlights the evolution of the MiSight® 1 day product. The resource reflects CooperVision’s broader commitment to advancing myopia management through ongoing research and innovation, while supporting ECPs in their conversations with patients, parents, and colleagues. To learn more about CooperVision’s myopia management research journey, read Progress in Focus at https://online.flippingbook.com/view/645323420/ or visit www.coopervision.com.
# # #
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
*INDICATIONS: MiSight® 1 day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
References:
1. Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8): 556-567.
2. Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci. 2022 Mar 1;99(3):204-212.
3. Chamberlain P, et al. Myopia Progression in Children on cessation of Dual-Focus contact lens wear: MiSight 1 day 7-year findings. Optom Vis Sci 2021;98:E-abstract 210049.
4. CVI data on file, 2022.
5. Chamberlain, Arumugam, Jones, et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97(E-abstract):200038]
6. Chamberlain, Arumugam, et al. Myopia progression cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.]
7. Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
8. Sulley A et al. Experience and subjective responses for children switched from single vision to dual focus myopia control daily disposable contact lenses. BCLA paper presentation 2021.
9. CVI data on file, 2026.
10. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.